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Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Doug Klein RN, BSN
Introduction 
Stevens-Johnson Syndrome (SJS) and 
Toxic Epidermal Necrolysis (TEN) are rare, 
cutaneous, severe, drug-induced 
hypersensitivity reactions marked by 
widespread inflammation of the 
epidermis, ending in necrosis and the 
eventual sloughing of tissue.  First 
described in 1922  by pediatricians Albert 
Stevens and Frank Johnson, both diseases 
are believed to be as a result of the same 
disease process.  They are the most serious 
of all drug-related hypersensitivity 
reactions which result in hospitalization 
(Ferrandiz-Perez & Garcia-Patos, 2013).
As a critical care nurse caring for a 
variety of trauma patients, it is crucial that 
staff is aware of potentially serious 
medication reactions.  Some of the most 
serious of these start out with vague 
symptoms and may appear benign.  
However, some are very serious and 
potentially fatal.  
Signs and Symptoms
Early signs/symptoms:
• Fever, malaise, fatigue and mucosal 
lesions, headache, bleeding
Later signs/symptoms:
• Marked erythema of skin leading to 
papules, vesicles and necrosis.  These 
start on the face neck and anterior 
trunk and may extend over the entire 
surface of the skin.
• Mucosal involvement, including ocular, 
GI, GU, genital and upper and the 
epithelial cells of the lower respiratory 
tree.  These areas are associated with 
heavy bleeding , scarring and long-term 
complications. 
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Disease TBSA % Mortality            Incidence/million    
SJS <10% 5% 2-6
TEN >30% 30% 0.2-1.2
(Mawson et al., 2015) (>10%, <30% is considered to be mixed SJS/TEN disease) (TBSA-total body surface area)
Statistics
Pathophysiology-Overview
SJS/TEN disease has long been presumed to appear as a result 
of an immune-mediated response to certain drug metabolites, 
although the exact mechanism of action has been poorly 
understood.  Evidence has established a genetic predisposition for 
illness to various Asian populations, leading to FDA 
recommendations for pre-therapy genetic testing.  Additional 
research has focused on the effects Vitamin A derivatives have on 
the disease process.
Pathophysiology
SJS/TEN is marked by the widespread eruption of macules and 
papules which eventually lead to skin necrosis and sloughing.  
Until recently, SJS/TEN has been thought to be an idiopathic 
illness.  Research seeking to clarify the genesis of the illness has 
found that morbidity can be a result of a genetic predisposition to 
a drug hypersensitivity reaction.  Genetic research has identified 
several combinations of Alleles and medications which when 
combined, increase the risk of illness.  Further research has sought 
understanding into the disease pathophysiology.  In a paper 
published by Mawson, Eriator and Karre (2015), the authors 
theorize that disease occurs when a drug metabolite damages the 
liver, the organ responsible for storage of Vitamin A, causing free-
retinoid molecules to spill into the circulation creating an acute, 
systemic Vitamin A toxicity.  Granulysin, a cytotoxic protein 
produced in massive quantities by both CD8+ T-Lymphocytes and 
natural killer cells is the most prevalent molecule found in SJS/TEN 
blisters.  Granulysin is believed to act as a cytokine for destructive 
retinoid molecules (such as retinoic acid), combined together are 
believed to be responsible for keratinocyte apoptosis seen in 
SJS/TEN.  As keratinocytes die off, the epidermis becomes 
detached from the dermis ending in tissue necrosis and sloughing 
(Teo & Walsh, 2016).  Although not fully understood, the authors 
theorize that CD8+ T-cells become hyperactive when exposed to 
extreme levels of retinol and overproduce Granulysin.  Granulysin
then attracts retinoic acid which are both cytotoxic and together 
cause keratinocytes to die off.  Keratinocytes make up 90% of the 
cells in the epidermis.
Many classes of medications have been linked to SJS/TEN, 
including anticonvulsants, antibiotics, NSAIDS, corticosteroids and 
allopurinol.  These medications increase circulating retinoid levels, 
either through hepatic release as a result of liver injury, or through 
the inhibition of metabolism which leads to higher circulating 
retinol derivatives, such as retinoic acid, a powerful cell-lysing 
agent (Mawson, Eriator, & Karre, 2015).  Hepatic injury could 
explain the extended prodromal illness seen in this disease as 
patients often present with vague illness which typically lasts for 
over a week prior to the onset of the more identifiable rash. 
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Understanding pathophysiology is key for treating and limiting 
the destructive mechanism for disease.  Provided that retinol 
toxicity is involved with SJS/TEN, plasmapheresis could be used to 
reduce circulating levels and mitigate the destructive effects 
which retinol contributes in this disease.  Plasmapheresis has 
been shown in small samples to reduce mortality versus typical 
treatment for patients with SJS/TEN (Mawson, 2015). 
Genetic predispositions have been positively established for 
people of Asian descent who carry the HLA-B1502 Allele when 
exposed to Carbamazepine.  The FDA recommends genetic 
testing prior to starting Asian patients on Carbamazepine therapy 
(Tangamornsukan, Chalyakunapruk, Somkrua, Lohitnavy, & 
Tassaneeyakui, 2013).  Studies have also linked a higher than 
normal incidence of SJS/TEN within the Indian population, 
particularly is they are HIV-positive (Patel, Barvaliya, Sharma & 
Tripathi, 2013).  HLA-A3101 has recently been identified as a 
phenytoin-associated risk among Japanese and Europeans 
(Pirmohamed et al., 2011).  Understanding genetic associations 
can help healthcare providers the mitigate risk through pre-
therapy testing.
Implications: Pathophysiology      
Rapid identification of disease is crucial for patients 
suffering from SJS/TEN as removal of the offending medication 
is critical for mitigating the effects of the illness.  Nursing 
should familiarize themselves with the symptoms and signs of 
progression as illness may advance quickly from SJS to TEN in 
as few as twelve hours (Poulson, Nielsen, & Poulsen, 2013).  
• Nursing should be watchful for signs or symptoms of 
decompensation due to respiratory failure or sepsis.  
• Pain management and the use of conscious sedation, 
especially during debridement and dressing changes will 
improve healing and health outcomes.  
• Treatment is best done in a specialized burn center.  
• The nurse should seek to coordinate a multi-disciplinary 
team approach(Cooper, 2012).   
• Long-term restrictive pulmonary disease is frequently seen 
with SJS/TEN and patients will often require long-term use 
of bronchodilators (British Journal of Medicine, 2015).
Conclusions:
Although SJS/TEN has been recognized illness for decades, 
recent advancements in genetics have identified strong 
predispositions to certain drug reactions, helping guide 
prescribers prior toward safe and effective treatment.  Patients 
at risk should be tested for susceptibility before starting 
therapy.  The use of plasmapheresis should be studied further 
to determine whether limiting free-retinoid compounds could 
mitigate the damage caused by disease.
Nursing: Implications:
Progression of SJS/TEN
Retinoid and Granulysin-mediated hypothesis
Of Stevens-Johnsons Syndrome/Toxic
Epidermal Necrolysis (SJS/TEN)
(Mawson, et al, 2015)
